Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BI-D1870
Cat. No.:
OB0225LY-0494
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
BI-D1870 is a small molecule compound that acts primarily as a selective GSK-3β inhibitor with significant effects on a variety of cell signaling pathways.
Synonym:
501437-28-1; 2-((3,5-Difluoro-4-hydroxyphenyl)amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; 2-(3,5-Difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7H-pteridin-6-one; 2-[(3,5-Difluoro-4-hydroxyphenyl)amino]-7,8-dihydro-5,7-dimethyl-8-(3-methylbutyl)-6(5H)-pteridone
CAS No.:
501437-28-1
Compound CID:
25023738
Formula:
C19H23F2N5O2
Formula Weight:
391.42
Specification
Relative Density:
1.297 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BI-D1870 can be used to study mechanisms of diabetes and neurodegenerative diseases.
Library Information
Targets:
S6 Kinase
Receptors:
Autophagy; Ribosomal S6 Kinase (RSK); RSK1; RSK2; RSK3; RSK4
Pathways:
MAPK; Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-7
Plate Location:
d6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
6.88 mg/mL; 17.56 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
